Published in Leukemia on September 30, 2010
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood (2011) 2.96
Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood (2013) 1.09
Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol (2016) 0.87
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL). Leukemia (2014) 0.86
Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience (2016) 0.76
Relationship between concussion and neuropsychological performance in college football players. JAMA (1999) 3.95
Value of body fat mass vs anthropometric obesity indices in the assessment of metabolic risk factors. Int J Obes (Lond) (2006) 3.40
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest (1996) 2.10
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum (2006) 1.96
Epidemiology of collegiate baseball injuries. Clin J Sport Med (1998) 1.85
Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res (2001) 1.82
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res (2001) 1.59
CD3 gamma contains a phosphoserine-dependent di-leucine motif involved in down-regulation of the T cell receptor. EMBO J (1994) 1.54
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A (1997) 1.47
Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia (1999) 1.45
In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia (2004) 1.44
Regulation and function of the CD3gamma DxxxLL motif: a binding site for adaptor protein-1 and adaptor protein-2 in vitro. J Cell Biol (1997) 1.42
Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer (2011) 1.42
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia (2001) 1.40
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol (2004) 1.39
Anorectal melanoma: surgical management guidelines according to tumour thickness. Br J Cancer (2003) 1.37
Nasal T-cell lymphoma and the lethal midline granuloma syndrome. Otolaryngol Head Neck Surg (1996) 1.32
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia (2013) 1.31
Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia (2006) 1.31
Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia (2005) 1.31
NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia (2012) 1.27
STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood (2001) 1.27
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity (2001) 1.26
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia (2009) 1.25
Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol (2000) 1.24
FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia (2007) 1.24
Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res (1995) 1.24
Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci U S A (1999) 1.22
The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood (1998) 1.20
Simulation of the electrical and mechanical gradient of the small intestine. Am J Physiol (1968) 1.17
Induction of carcinoma cell migration on vitronectin by NF-kappa B-dependent gene expression. Mol Biol Cell (1995) 1.16
Merkel cell carcinoma--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol (2011) 1.12
Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood (1998) 1.11
Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol (1999) 1.10
MHC class II ligation induces CD58 (LFA-3)-mediated adhesion in human T cells. Exp Clin Immunogenet (1998) 1.10
Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. J Hosp Infect (2013) 1.07
BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A (1998) 1.07
Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia (2008) 1.07
Role of the T cell receptor ligand affinity in T cell activation by bacterial superantigens. J Biol Chem (2001) 1.05
Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. Leukemia (2011) 1.05
Two distinct pathways exist for down-regulation of the TCR. J Immunol (1998) 1.04
Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia (2013) 1.03
Distinct domains of the CD3-gamma chain are involved in surface expression and function of the T cell antigen receptor. J Biol Chem (1995) 1.02
Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells. J Immunol (1999) 1.01
Role of CD3 gamma in T cell receptor assembly. J Cell Biol (1996) 1.01
In situ T cells in melanoma. Cancer Immunol Immunother (1999) 1.01
BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report. Br J Dermatol (2012) 1.01
Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol (2000) 1.00
The role of caspase 3 and BclxL in the action of interleukin 7 (IL-7): a survival factor in activated human T cells. Cytokine (1998) 1.00
Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Int J Obes (Lond) (2006) 1.00
Frequency of distribution of inflammatory cytokines IL-1, IL-6 and TNF-alpha gene polymorphism in patients with obstructive sleep apnea. J Physiol Pharmacol (2008) 0.99
Hypercalcaemia in the accelerated phase of chronic myelogenous leukaemia: no relationship to the phenotype of the blast cells. Scand J Haematol (1985) 0.99
TCRzeta is transported to and retained in the Golgi apparatus independently of other TCR chains: implications for TCR assembly. Eur J Immunol (1999) 0.98
Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther (2001) 0.97
In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol (1999) 0.96
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol (2006) 0.96
The phosphorylation state of CD3gamma influences T cell responsiveness and controls T cell receptor cycling. J Biol Chem (1998) 0.95
Immunomodulating activity of heparin. FASEB J (1991) 0.95
Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost (1997) 0.95
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res (1998) 0.95
Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer (2004) 0.94
Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest (1996) 0.94
Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther (1998) 0.94
Lichen planus associated with Becker's nevus. J Am Acad Dermatol (1998) 0.94
Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J (2001) 0.93
Leptin receptors. Eur J Med Res (2010) 0.93
Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood (2000) 0.93
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. Br J Cancer (2010) 0.93
Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int J Cancer (2001) 0.93
Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res (1999) 0.93
CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes. J Immunol (2000) 0.92
Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Exp Clin Endocrinol Diabetes (2005) 0.92
Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci U S A (1998) 0.92
Heterogeneity of antibody response to myobacterial antigens in different clinical manifestations of pulmonary tuberculosis. J Physiol Pharmacol (2007) 0.92
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother (1996) 0.91